



Joint Symposium 1

EAU/EANM Joint Symposium – Oncology and Theranostics Committee

Sunday, October 18, 09:45–11:15

Session Title

Changing Care: Highlights on Level I Therapy Trials in Prostate Cancer

Chairpersons

Wolfgang Fendler (Essen, Germany)

Jochen Walz (Marseille, France)

Programme

- 09:45–10:05 **Jeremie Calais** (Los Angeles, United States): Highlights on Alpha Therapy: The New Kid on the Block?
- 10:05–10:30 **Désirée Deandreis** (Paris, France): Highlights on Beta Therapy: How Will This Impact Future Management?
- 10:30–10:55 **Louise Emmett** (Sydney, Australia): Combination RLT is Coming: ENZA_p, AlphaBet and More
- 10:55–11:15 **Bertrand Tombal** (Manchester, United Kingdom): How to Put This in Clinical Context?

Educational Objectives

1. Understand the evidence supporting alpha- and beta-emitting PSMA-targeted radionuclide therapies in prostate cancer.
2. Critically appraise recent trials evaluating combination strategies of radionuclide therapy with systemic treatments.
3. Translate trial evidence into clinical practice, integrating nuclear medicine and urological perspectives for patient-centred decision-making.

Summary

Radionuclide therapy has rapidly evolved into a key therapeutic pillar in advanced prostate cancer, supported by robust evidence from randomised clinical trials. This joint EAU/EANM symposium highlights recent clinical data on alpha- and beta-emitting radioligand therapies, as well as emerging combination approaches incorporating androgen-receptor pathway inhibitors and other systemic treatments. International experts from nuclear medicine and urology will discuss trial outcomes, safety considerations, and their implications for clinical management, bridging disciplines to provide practical guidance on how these data are reshaping standards of care across prostate cancer disease stages.

Key Words

Radionuclide Therapy; Prostate Cancer; PSMA; Alpha Therapy; Beta Therapy; Combination Therapy; Theranostics